Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Baxter
Dow
Mallinckrodt
Boehringer Ingelheim

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,612,208

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,612,208 protect, and when does it expire?

Patent 7,612,208 protects LENVIMA and is included in one NDA.

This patent has forty-three patent family members in twenty-seven countries.

Summary for Patent: 7,612,208
Title:Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide or the solvate of the salt and a process for preparing the same
Abstract: A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.
Inventor(s): Matsushima; Tomohiro (Tsukuba, JP), Nakamura; Taiju (Kamisu, JP), Yoshizawa; Kazuhiro (Kamisu, JP), Kamada; Atsushi (Tsukuba, JP), Ayata; Yusuke (Kamisu, JP), Suzuki; Naoko (Ushiku, JP), Arimoto; Itaru (Tokyo, JP), Sakaguchi; Takahisa (Tsukuba, JP), Gotoda; Masaharu (Tsukuba, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:10/577,531
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Dosage form;

Drugs Protected by US Patent 7,612,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,612,208

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-430939Dec 25, 2003
PCT Information
PCT FiledDecember 22, 2004PCT Application Number:PCT/JP2004/019223
PCT Publication Date:July 14, 2005PCT Publication Number: WO2005/063713

International Family Members for US Patent 7,612,208

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004309217   Start Trial
Brazil PI0418200   Start Trial
Canada 2543650   Start Trial
China 100569753   Start Trial
China 101337931   Start Trial
China 101337932   Start Trial
China 101337933   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Mallinckrodt
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.